Company intelligence / Profile preview

Trajectum Pharma

Ownership: Private
Development stage: Preclinical

Overview

Trajectum Pharma develops novel immunotherapies targeting autoimmune diseases. Its lead program uses ex vivo modified autologous dendritic cells loaded with a proprietary peptide to induce immune tolerance in rheumatoid arthritis. The company’s main clinical study (“TOLERANT” trial) aims to demonstrate safety and feasibility of this approach. Early results focus on safety, immune response modulation, and reduction of disease activity; the study remains ongoing as of March 2025.

Therapeutic areas: Immunology
Modalities: mRNA-based therapiesCell therapies (tolerogenic dendritic cells)Lipid nanoparticles (for delivery)Peptide-loaded autologous dendritic cells
Industry: Biotech

Drug pipeline

1 asset

TolDCB29

Partnerships

University Medical Center Utrecht (academic collaboration/sponsor for the TOLERANT trial)

Beyond the preview

Go deeper on Trajectum Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trajectum Pharma.

Explore the full profile